These are the posts from the How we think section that have been tagged with Biosimilars.
To see all tags used in our posts, click here.
|13th June 2016
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
|29th September 2015
With pharma in the midst of a patent cliff, portfolios of treatments are becoming more and more common, and the need for a clear co-positioning strategy has never been greater.
Head of Brand Strategy Jenna Earl talks us through the three most important things to understand about portfolio positioning in pharma.
|23rd September 2015
Recently, Blue Latitude Health worked with a global pharmaceutical brand to develop a strategy for dealing with the introduction of biosimilars to the market. Their product, a treatment in the gastroenterology therapy area, had recently come off patent and a biosimilar was about to launch. Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars.
|12th March 2015
The modern pharmaceutical market can be saturated with competing products, from bio-similars, to same in-class, to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by.
Consultant Mark Assenti talks through the use of biomarkers in pharma marketing and where it's headed in 2015.